Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy

<table>Overall, disease-specific, and progression-free survival. Median progression-free and overall survival were 6.4 and 8.0 months, respectively. Median cutaneous squamous cell carcinoma- (cSCC-) specific survival was not reached. cSCC-specific and overall survival were 51% (95% confidence interval, 26–85%) and 40% (95% confidence interval, 14–66%) at 2 years.</table>

Journal of Skin Cancer

fig2

Figure 2

Figure 2: Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy 